Eli Lilly's growth rests on tirzepatide, sold as Mounjaro and Zepbound, and third-quarter 2026 revenue rose 39%. Lilly now accepts lower U.S. prices for wider access, so the question is whether patient numbers grow faster than prices fall.
A prescription filled at a pharmacy may begin years earlier in an Eli Lilly laboratory and factory. Lilly discovers, makes and sells patented prescription medicines, mostly in the United States. One molecule now carries the company. It is tirzepatide, sold as Mounjaro and Zepbound, the core of Lilly's diabetes and obesity business. Lilly earns money when a medicine works well enough that insurers and government programmes agree to cover it.
Insurers and government programmes, known as payers, decide whether a drug is covered and what patients pay themselves. Drug makers compete for that place on results, safety and ease of use. They also offer rebates (money returned to payers after the sale). Lilly keeps what is left after rebates and government discounts, minus the cost of research, production and launches. Factories are a large cost. Regulators inspect them, and adding capacity takes years and heavy spending. For tirzepatide, and so for Lilly, three things decide the outcome: how many patients take it, the net price, and whether Lilly can make enough.
Create a free account to unlock the rest of this report and access all published research.
This report is general, non-personalized research provided solely for informational and educational purposes. It is not financial or investment advice, a personalized recommendation, an offer to the public, a solicitation, an instruction to buy, sell or hold a financial instrument, or an invitation to engage in an investment activity. ReasyPort is not an authorised or regulated investment firm and does not provide a MiFID II investment service.
This report is based on primary and public sources identified in the report, including issuer filings, annual and interim reports, regulated announcements, investor-relations materials, market data and, where relevant, institutional macroeconomic publications. Facts should be read separately from interpretations, estimates and opinions.
Text, analyses, summaries, translations and charts may be produced with the support of Artificial Intelligence and are subjected to deterministic data and consistency checks before publication. These controls reduce, but cannot eliminate, errors, omissions or incorrect interpretations. Editorial responsibility for publication remains with the producer identified above.
ReasyPort View labels, fair values, forecasts, scenarios, price references and other forward-looking statements are editorial estimates or opinions, not facts or trading instructions. They depend on the assumptions, methodology, market price and information available on the stated reference date and may change without notice. The report is not monitored or updated in real time.
Any relationship, compensation, material holding or other circumstance known to ReasyPort that could reasonably impair the objectivity of a report must be disclosed with that report. Questions, corrections and potential conflicts may be reported through the legal contact shown above.
Public and primary sources, automated extraction and data providers may contain material errors, omissions, inaccuracies, restatements or delays. Accuracy, completeness and timeliness are therefore not guaranteed, and important information should be checked against the original source before it is used.
To the maximum extent permitted by applicable law, ReasyPort, the author, the publisher and the persons involved in producing the report are not liable for losses arising from decisions made solely in reliance on this report. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Any investment decision should be made independently, if appropriate with the support of a licensed financial adviser. Investments in financial instruments involve risks, including the possible partial or total loss of invested capital.
Research methodology, assumptions and disclosuresMeaning of ReasyPort View